What is the current valuation of the Geriatric Medicine Market as of 2024?

The Geriatric Medicine Market was valued at 429.99 USD Billion in 2024. Read More

What is the projected market size for the Geriatric Medicine Market in 2035?

The market is projected to reach 699.3 USD Billion by 2035. Read More

What is the expected CAGR for the Geriatric Medicine Market during the forecast period 2025 - 2035?

The expected CAGR for the Geriatric Medicine Market during 2025 - 2035 is 4.52%. Read More

Which age group is projected to have the highest market valuation in the Geriatric Medicine Market?

The age group of 75-84 years is projected to have a market valuation of 250.0 USD Billion. Read More

What are the leading companies in the Geriatric Medicine Market?

Key players include Johnson & Johnson, Pfizer Inc., Novartis AG, and Bristol-Myers Squibb Company. Read More

How does the market valuation for cardiovascular diseases compare to neurological disorders?

The market valuation for cardiovascular diseases is projected at 135.0 USD Billion, while neurological disorders are at 110.0 USD Billion. Read More

What is the projected market size for telemedicine care in the Geriatric Medicine Market?

Telemedicine care is projected to reach a market size of 209.3 USD Billion. Read More

Which diagnostic procedure is expected to have the highest market valuation?

Functional assessment is expected to have the highest market valuation at 135.0 USD Billion. Read More

What is the market size for at-home care services in the Geriatric Medicine Market?

At-home care services are projected to reach a market size of 150.0 USD Billion. Read More

How does the market for frailty assessment compare to nutritional assessment?

Frailty assessment is projected at 49.8 USD Billion, whereas nutritional assessment is at 80.0 USD Billion. Read More

Geriatric Medicine Market

ID: MRFR/HC/29454-HCR

100 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Geriatric Medicine Market Research Report By Age Group (65-74 years, 75-84 years, 85 years and above), By Target Organ/Condition (Cardiovascular diseases, Neurological disorders, Musculoskeletal diseases, Oncological diseases, Respiratory diseases), By Diagnostic Procedures (Geriatric assessment, Functional assessment, Cognitive assessment, Nutritional assessment, Frailty assessment), By Service Delivery Model (Outpatient care, Inpatient care, At-home care, Telemedicine care) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Age Group (USD Billion)
  1. 4.1.1 65-74 years
  2. 4.1.2 75-84 years
  3. 4.1.3 85 years and above
2. 4.2 Healthcare, BY Target Organ/Condition (USD Billion)
  1. 4.2.1 Cardiovascular diseases
  2. 4.2.2 Neurological disorders
  3. 4.2.3 Musculoskeletal diseases
  4. 4.2.4 Oncological diseases
  5. 4.2.5 Respiratory diseases
3. 4.3 Healthcare, BY Diagnostic Procedures (USD Billion)
  1. 4.3.1 Geriatric assessment
  2. 4.3.2 Functional assessment
  3. 4.3.3 Cognitive assessment
  4. 4.3.4 Nutritional assessment
  5. 4.3.5 Frailty assessment
4. 4.4 Healthcare, BY Service Delivery Model (USD Billion)
  1. 4.4.1 Outpatient care
  2. 4.4.2 Inpatient care
  3. 4.4.3 At-home care
  4. 4.4.4 Telemedicine care
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer Inc. (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis AG (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb Company (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AbbVie Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co., Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca PLC (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Gilead Sciences, Inc. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi S.A. (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
  10. 5.2.10 Roche Holding AG (CH)
    1. 5.2.10.1 Financial Overview
    2. 5.2.10.2 Products Offered
    3. 5.2.10.3 Key Developments
    4. 5.2.10.4 SWOT Analysis
    5. 5.2.10.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY AGE GROUP
4. 6.4 US MARKET ANALYSIS BY TARGET ORGAN/CONDITION
5. 6.5 US MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
6. 6.6 US MARKET ANALYSIS BY SERVICE DELIVERY MODEL
7. 6.7 CANADA MARKET ANALYSIS BY AGE GROUP
8. 6.8 CANADA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
9. 6.9 CANADA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
10. 6.10 CANADA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY AGE GROUP
13. 6.13 GERMANY MARKET ANALYSIS BY TARGET ORGAN/CONDITION
14. 6.14 GERMANY MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
15. 6.15 GERMANY MARKET ANALYSIS BY SERVICE DELIVERY MODEL
16. 6.16 UK MARKET ANALYSIS BY AGE GROUP
17. 6.17 UK MARKET ANALYSIS BY TARGET ORGAN/CONDITION
18. 6.18 UK MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
19. 6.19 UK MARKET ANALYSIS BY SERVICE DELIVERY MODEL
20. 6.20 FRANCE MARKET ANALYSIS BY AGE GROUP
21. 6.21 FRANCE MARKET ANALYSIS BY TARGET ORGAN/CONDITION
22. 6.22 FRANCE MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
23. 6.23 FRANCE MARKET ANALYSIS BY SERVICE DELIVERY MODEL
24. 6.24 RUSSIA MARKET ANALYSIS BY AGE GROUP
25. 6.25 RUSSIA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
26. 6.26 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
27. 6.27 RUSSIA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
28. 6.28 ITALY MARKET ANALYSIS BY AGE GROUP
29. 6.29 ITALY MARKET ANALYSIS BY TARGET ORGAN/CONDITION
30. 6.30 ITALY MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
31. 6.31 ITALY MARKET ANALYSIS BY SERVICE DELIVERY MODEL
32. 6.32 SPAIN MARKET ANALYSIS BY AGE GROUP
33. 6.33 SPAIN MARKET ANALYSIS BY TARGET ORGAN/CONDITION
34. 6.34 SPAIN MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
35. 6.35 SPAIN MARKET ANALYSIS BY SERVICE DELIVERY MODEL
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TARGET ORGAN/CONDITION
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY SERVICE DELIVERY MODEL
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY AGE GROUP
42. 6.42 CHINA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
43. 6.43 CHINA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
44. 6.44 CHINA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
45. 6.45 INDIA MARKET ANALYSIS BY AGE GROUP
46. 6.46 INDIA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
47. 6.47 INDIA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
48. 6.48 INDIA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
49. 6.49 JAPAN MARKET ANALYSIS BY AGE GROUP
50. 6.50 JAPAN MARKET ANALYSIS BY TARGET ORGAN/CONDITION
51. 6.51 JAPAN MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
52. 6.52 JAPAN MARKET ANALYSIS BY SERVICE DELIVERY MODEL
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
57. 6.57 MALAYSIA MARKET ANALYSIS BY AGE GROUP
58. 6.58 MALAYSIA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
59. 6.59 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
60. 6.60 MALAYSIA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
61. 6.61 THAILAND MARKET ANALYSIS BY AGE GROUP
62. 6.62 THAILAND MARKET ANALYSIS BY TARGET ORGAN/CONDITION
63. 6.63 THAILAND MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
64. 6.64 THAILAND MARKET ANALYSIS BY SERVICE DELIVERY MODEL
65. 6.65 INDONESIA MARKET ANALYSIS BY AGE GROUP
66. 6.66 INDONESIA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
67. 6.67 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
68. 6.68 INDONESIA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
69. 6.69 REST OF APAC MARKET ANALYSIS BY AGE GROUP
70. 6.70 REST OF APAC MARKET ANALYSIS BY TARGET ORGAN/CONDITION
71. 6.71 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
72. 6.72 REST OF APAC MARKET ANALYSIS BY SERVICE DELIVERY MODEL
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY AGE GROUP
75. 6.75 BRAZIL MARKET ANALYSIS BY TARGET ORGAN/CONDITION
76. 6.76 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
77. 6.77 BRAZIL MARKET ANALYSIS BY SERVICE DELIVERY MODEL
78. 6.78 MEXICO MARKET ANALYSIS BY AGE GROUP
79. 6.79 MEXICO MARKET ANALYSIS BY TARGET ORGAN/CONDITION
80. 6.80 MEXICO MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
81. 6.81 MEXICO MARKET ANALYSIS BY SERVICE DELIVERY MODEL
82. 6.82 ARGENTINA MARKET ANALYSIS BY AGE GROUP
83. 6.83 ARGENTINA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
84. 6.84 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
85. 6.85 ARGENTINA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TARGET ORGAN/CONDITION
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SERVICE DELIVERY MODEL
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
99. 6.99 REST OF MEA MARKET ANALYSIS BY AGE GROUP
100. 6.100 REST OF MEA MARKET ANALYSIS BY TARGET ORGAN/CONDITION
101. 6.101 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES
102. 6.102 REST OF MEA MARKET ANALYSIS BY SERVICE DELIVERY MODEL
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TARGET ORGAN/CONDITION, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TARGET ORGAN/CONDITION, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY DIAGNOSTIC PROCEDURES, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY DIAGNOSTIC PROCEDURES, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY SERVICE DELIVERY MODEL, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY SERVICE DELIVERY MODEL, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.2.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.2.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.2.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.3.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.3.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.3.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.4.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.4.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.4.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.5.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.5.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.5.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.6.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.6.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.6.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.7.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.7.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.7.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.8.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.8.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.8.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.9.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.9.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.9.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.10.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.10.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.10.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.11.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.11.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.11.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.12.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.12.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.12.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.13.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.13.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.13.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.14.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.14.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.14.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.15.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.15.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.15.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.16.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.16.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.16.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.17.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.17.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.17.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.18.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.18.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.18.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.19.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.19.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.19.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.20.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.20.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.20.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.21.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.21.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.21.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.22.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.22.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.22.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.23.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.23.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.23.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.24.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.24.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.24.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.25.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.25.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.25.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.26.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.26.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.26.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.27.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.27.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.27.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.28.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.28.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.28.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.29.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.29.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.29.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY AGE GROUP, 2025-2035 (USD Billion)
  2. 7.30.2 BY TARGET ORGAN/CONDITION, 2025-2035 (USD Billion)
  3. 7.30.3 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion)
  4. 7.30.4 BY SERVICE DELIVERY MODEL, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Geriatric Medicine Market Segmentation

Geriatric Medicine Market By Age Group (USD Billion, 2025-2035)

65-74 years
75-84 years
85 years and above

Geriatric Medicine Market By Target Organ/Condition (USD Billion, 2025-2035)

Cardiovascular diseases
Neurological disorders
Musculoskeletal diseases
Oncological diseases
Respiratory diseases

Geriatric Medicine Market By Diagnostic Procedures (USD Billion, 2025-2035)

Geriatric assessment
Functional assessment
Cognitive assessment
Nutritional assessment
Frailty assessment

Geriatric Medicine Market By Service Delivery Model (USD Billion, 2025-2035)

Outpatient care
Inpatient care
At-home care
Telemedicine care

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”